LifeSci Capital analyst Cory Jubinville initiated coverage of Mereo BioPharma (MREO) with an Outperform rating and $10 price target
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MREO: